Napolitano A, Cesura A M, Da Prada M
Pharma Division, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
J Neural Transm Suppl. 1995;45:35-45.
The action of dopamine (DA) released in the synaptic cleft is mainly terminated by its reuptake and catabolism by the enzymes monoamine oxidase (MAO) and catechol O-methyltransferase (COMT). Preclinical data show that the reduction of the catabolism of DA elicited by MAO and COMT inhibitors leads to an enhancement of DA neurotransmission. Moreover, there is evidence suggesting that MAO-B inhibition might protect DA neurons from oxidative stress. Nevertheless, due to differences in enzyme localization and activity between man and rodents, results obtained in experimental animals might not reflect the actual situation in humans. Today the availability of potent and selective MAO and COMT inhibitors makes it feasible for the clinician to test whether the blockade of catabolic enzymes would result in a symptomatic improvement in Parkinsonian patients, and whether MAO-B inhibition might additionally exert a neuroprotective effect.
突触间隙中释放的多巴胺(DA)的作用主要通过其被单胺氧化酶(MAO)和儿茶酚-O-甲基转移酶(COMT)重新摄取和分解代谢而终止。临床前数据表明,MAO和COMT抑制剂引起的DA分解代谢减少会导致DA神经传递增强。此外,有证据表明MAO-B抑制可能保护DA神经元免受氧化应激。然而,由于人与啮齿动物之间酶定位和活性的差异,实验动物中获得的结果可能无法反映人类的实际情况。如今,强效和选择性MAO和COMT抑制剂的可得性使临床医生能够测试分解代谢酶的阻断是否会导致帕金森病患者症状改善,以及MAO-B抑制是否可能额外发挥神经保护作用。